LUNG CANCER AND DEEP VENOUS THROMBOSIS
DOI:
https://doi.org/10.5457/ams.v43i1%20-%202.363Keywords:
lung cancer, deep venous thrombosisAbstract
Introduction: Malignant diseases including lung cancer are the risk for development of deep venous thrombosis (DVT) and pulmonary thromboembolism (PTE). Objective: To show the number of DVT in patients with lung cancer treated in Clinic for pulmonary diseases and TB “Podhrastovi” in three-year period: from 2012-2014. Material and methods: This is the retrospective study in which we present the number of various types of lung cancer treated in three-year period in Clinic”Podhrastovi”, number and per cent of DVT in different types of lung carcinoma, number and per cent of DVT of all diagnosed DVT in lung carcinoma according to the type of carcinoma. Results: In three-year period (from 2012. to 2014.year) 1609 patients with lung cancer were treated in Clinic for pulmonary diseases and TB “Podhrastovi” Clinical Centre of Sarajevo University. 26 patients: 20 men middle –aged 59.9 years and 6 women middle- aged 63.1 years or 1.62 % of all patients with lung cancer had diagnosed DVT. Of all 26 patients with lung cancer and diagnosed DVT 3 patients (11.53%) had planocellular cancer, 1 patient (3.85%) had squamocellular cancer, 13 (50%) had adenocarcinoma, 2 (7.7 %) had NSCLC, 1 (3.65 %) had microcellular cancer, 6 (23.08%) had histological non-differentiated lung carcinoma. Conclusion: Malignant diseases, including lung cancer, are the risk factor for development of DVT. It is important to consider the including anticoagulant prophylaxis in these patients and so to slow down the course of diseases in these patients.
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
